Document Type
Article
Publication Date
5-25-2021
Publication Title
Oncotarget
Abstract
LKB1-signaling has prominent roles in cancer development and metastasis. This report evaluates LKB1-signaling pathway gene expression associations with patient survival in overall breast cancer, specific subtypes, as well as pre- and post-chemotherapy. Subtypes analyzed were based on intrinsic molecular subtyping and traditional biomarker classifications. Intrinsic molecular subtypes included were Luminal-A, Luminal-B, HER2-enriched, and Basal-like. The biomarker subtypes assessed were Estrogen-Receptor Positive (ER+) and Negative (ER-), Wild-Type TP53 (WT-TP53) & Mutant-TP53, and Triple-Negative Breast Cancer (TNBC). Additionally, comparisons were made between these subtypes and breast cancer overall, and analyses between LKB1 signaling to patient survival before and after chemotherapy were made. We used the Kaplan-Meier Online Tool (KM Plotter) to correlate the relationship between mRNA expression of known LKB1 scaffolding proteins (CAB39 and LYK5), and downstream signaling targets (AMPK, MARK1, MARK2, MARK3, MARK4, NUAK1, NUAK2, PAK1, SIK1, SIK2, BRSK1, BRSK2, SNRK, and QSK), and patient survival across each subtype and treatment group. Our findings provide evidence that LKB1-signaling is associated with improved survival in overall breast cancer. Stratification into breast cancer subtypes show a more complicated relationship; NUAK2, for example, is correlated with improved survival in ER- but is worse in ER+ breast cancer. In evaluating the association of LKB1-signaling pathway expression with relapse free survival of varying breast cancer tumors exposed to chemotherapy or treatment-naive tumors, our data provides baseline knowledge for understanding the pathway dynamics that affect survival and therefore are linked to pathology. This establishes a foundation for studying LKB1 targets with the goal of identifying druggable targets.
First Page
1110
Last Page
1115
Volume
12
Issue
11
Publisher
Impact Journal
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Recommended Citation
Nguyen, Khoa; Rivera, Andrew; Alzoubi, Madlin; Wathieu, Henri; Dong, Shengli; Yousefi, Hassan; Matossian, Margarite; Alahari, Suresh; Drewry, David; Burow, Matthew; and Collins-Burow, Bridgette, "Evaluation of Liver Kinase B1 Downstream Signaling Expression in Various Breast Cancers and Relapse Free Survival After Systemic Chemotherapy Treatment" (2021). School of Medicine Faculty Publications. 6.
https://digitalscholar.lsuhsc.edu/som_facpubs/6
10.18632/ONCOTARGET.27929
File Format
File Size
859 KB